Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
MUSC Foundation for Research Development Patents
Assignee:
MUSC Foundation for Research Development
Address:
Charleston, SC
No. of patents:
35
Patents:












Patent Number Title Of Patent Date Issued
8569225 Targeting complement factor H for treatment of diseases October 29, 2013
The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the co
8568995 Methods for assessing modified LDL immune complexes in subjects having or at risk of coronary ar October 29, 2013
The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes.
8241905 Self-assembling cell aggregates and methods of making engineered tissue using the same August 14, 2012
A composition comprising a plurality of cell aggregates for use in the production of engineered organotypic tissue by organ printing. A method of making a plurality of cell aggregates comprises centrifuging a cell suspension to form a pellet, extruding the pellet through an orifice, and
8101371 Methods for the diagnosis of genitourinary cancer January 24, 2012
Methods for the diagnosis of genitourinary (GU) cancer are provided. In particular, urine has been found to contain significant levels of thromboxane receptor .beta. (TP.beta.) methods for diagnosing GU cancer. Methods for assessing treatment, prognosing and staging GU cancers, as we
8093393 Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer January 10, 2012
The present invention relates to cationic ceramides, their dihydro-analogs and aromatic analogs and their derivatives, comprising a pyridinium group. Also provided are methods for making cationic ceramides comprising a pyridinium group, and their use for treating or preventing diseas
8014847 Systems and methods for detecting deception by measuring brain activity September 6, 2011
Methods for determining whether the brain activity of a human subject in response to a stimulus of interest or question of interest is characteristic of a state of interest, such as a deceptive state or a truthful state, are disclosed. Some methods include the use of control question
8007804 Complement receptor 2 targeted complement modulators August 30, 2011
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a comple
7999082 Anti-factor B antibodies August 16, 2011
Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complem
7981616 Enhanced detection of RNA using a panel of truncated gene-specific primers for reverse transcrip July 19, 2011
The present invention provides truncated gene-specific primers in panels that can be used during the reverse transcription step of RT-PCR to increase signal detection of cancer gene markers in a tissue sample. Also provided are forward and reverse primers for RT-PCR. Methods of using the
7897759 Metabolically stable puromycin analogs March 1, 2011
Disclosed are structurally modified, metabolically stable nucleosides having antitumor activity wherein the formation of toxic metabolites is blocked and antimicrobial activity. The disclosure further relates to pharmaceutical compositions comprising one or more disclosed modified nu
7888319 Compositions and methods for promoting wound healing and tissue regeneration February 15, 2011
Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
7824857 Methods and compositions for diagnosing epithelial cell cancer November 2, 2010
Provided is a method for detecting metastases of epithelial cancers, comprising detecting in non-primary tissue overexpression of a nucleic acid of KS1/4, or detecting in non-primary tissue overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 a
7759304 Targeting complement factor H for treatment of diseases July 20, 2010
The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the co
7732197 Tissue-specific and target RNA-specific ribozymes June 8, 2010
The present invention relates to multi-ribozymes and their use to target RNA in a tissue-specific, target RNA-specific, or pathogen-specific manner for the treatment of cancers, proliferative disease, and bacterial, parasitic and viral infections. More specifically, the present inven
7423025 L-nucleosides as ligands to adenosine receptors September 9, 2008
Disclosed herein are compounds having Formula I, which are non-natural L-adenosine analogs. Also disclosed are their methods of making. Still further, disclosed are the uses of the disclosed compounds to treat cardiovascular disease, ischemia related injuries; and neurodegenerative d
7396659 Inhibitors of nitric oxide synthase to treat type 1 diabetes July 8, 2008
A method for treating type 1 diabetes in a human in need of such treatment, comprising administering to the human a biologically effective amount of at least one inhibitor of inducible nitric oxide synthase or a pro-inflammatory cytokine, wherein the inhibitor is an inhibitor of HMG-
7087895 Electrospray ionization using pointed fibers August 8, 2006
A pointed carbon fiber electrospray ionization emitter has a length of electrically conductive fiber that is present within a lumen of a microfluidic device, and protrudes from the terminus. A point is present on an end of the electrically conductive fiber, or the electrically conduc
7049058 Methods for suppressing the induction of nitric oxide synthase in a cell May 23, 2006
Disclosed are methods for suppressing the induction of inducible nitric oxide synthase in a cell comprising contacting said cell with an effective amount of at least one induction suppressor of inducible nitric oxide synthase or a cytokine are disclosed. The induction suppressor can
6967076 Method for producing recombinant cells for detecting HIV November 22, 2005
Recombinant expression vectors and methods are provided for detecting HIV and monitoring HIV drug resistance. The method comprises: taking a culture of cells; adding a recombinant viral vector into the culture to transduce the cells, the recombinant viral vector comprising a reporter seq
6900010 Compositions and methods for detecting human immunodeficiency virus May 31, 2005
Methods are provided for screening natural and synthetic anti-HIV agents using recombinant cells that are rendered susceptible to productive infection of various strains, subtypes or clades of HIV from both laboratory and clinical isolates. The method comprises: taking a culture of r
6890514 Methods for determining risk of developing cervical cancer May 10, 2005
The present invention relates generally to a method of identifying a subject having an increased risk of developing cervical cancer based on levels of IGF-II in serum and levels of EGF-R and HPV-E6/E7 in cervical epithelial cells and in serum.
6884576 Methods of monitoring HIV drug resistance April 26, 2005
A method is provided for detecting a presence of HIV virus in a sample comprising: taking a culture of recombinant cells which (a) are capable of cell division, (b) express CD4 receptor and one or more additional cell surface receptors necessary to allow the HIV virus to infect, (c) enab
6734166 Method of reducing aluminum levels in the central nervous system May 11, 2004
A method of reducing aluminum concentrations in the central nervous system of a subject (e.g., a patient afflicted with Alzheimer's disease or at risk of developing Alzheimer's disease) comprises administering to subject a PYY receptor agonist in an amount effective to reduce aluminum
6720413 Methods and compositions for diagnosis and treatment of cancer April 13, 2004
The present invention relates to a novel gene, CaSm, that is highly expressed in cancer tissues and cell lines, especially pancreatic cancer. The full length cDNA of CaSm encodes a protein of 133 amino acids. CaSm contains the two Sm motifs found in the common snRNP proteins, with the
6511800 Methods of treating nitric oxide and cytokine mediated disorders January 28, 2003
The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adre
6410013 Viral vectors for use in monitoring HIV drug resistance June 25, 2002
Recombinant expression vectors and methods are provided for detecting HIV and monitoring HIV drug resistance. The method comprises: taking a culture of cells; adding a recombinant viral vector into the culture to transduce the cells, the recombinant viral vector comprising a reporter seq
6406911 Compositions and methods for sensitive detection of HIV infection and monitoring of drug resista June 18, 2002
A method is provided for detecting a presence of HIV virus in a sample comprising: taking a culture of recombinant cells which (a) are capable of cell division, (b) express CD4 receptor and one or more additional cell surface receptors necessary to allow the HIV virus to infect, (c) enab
6399328 Methods and compositions for diagnosis and treatment of breast cancer June 4, 2002
The present invention relates to a novel gene, Di12, that is differentially expressed as a 1.35 kb RNA in breast cancer tissues and cell lines, and in several normal tissues. The full length cDNA encodes a protein of 339 amino acids. Antibodies to the gene product were developed to inves
6271359 Tissue-specific and pathogen-specific toxic agents and ribozymes August 7, 2001
The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the
6190402 Insitu formable and self-forming intravascular flow modifier (IFM) and IFM assembly for deployme February 20, 2001
An intravascular flow modifier (IFM) for use in a vessel has an outer layer formed of a strand configured as a longitudinally oriented coil of adjacent helical loops extending between a first end and a second end of the outer layer. The outer layer is secured in the vessel by at least so
6090125 Anatomically shaped vasoocclusive device and method of making the same July 18, 2000
This invention is an occlusive device for inserting into body cavities or vesicles. More particularly, it is a vasoocclusive device which, as used, is in the approximate shape of an anatomical cavity. It may be ultimately deployed as a substantially spherical shape in the operable config
6071710 Antikinin compounds and uses thereof June 6, 2000
An analog of the peptide consisting of RPPGF (SEQ ID N0:1) is provided. Mimetics of RPPGF (SEQ ID NO:1) and its retropeptide, FGPPR, are also provided. A peptide is provided having an antikinin activity and having the sequence X.sub.1 -R-P-P-G-F-X.sub.2 (SEQ ID NO:5), X.sub.1 -F-G-P-
5948616 Methods and compositions of correlating tissue kallikrein gene promoter polymorphisms with essen September 7, 1999
A method is provided for identifying a human subject as having an increased or decreased risk of developing essential hypertension, comprising determining the presence in the subject of an allele in the promoter region of the subject's tissue kallikrein gene correlated with an increa
5912019 Compounds for reducing ischemia/reperfusion injury June 15, 1999
Disclosed herein are compositions containing NO donors, inhibitors of iNOS induction, and endopeptidase inhibitors, and methods for their use for combating injury induced by ischemia and reperfusion following ischemic episodes.
5766219 Anatomically shaped vasoocclusive device and method for deploying same June 16, 1998
This invention is an occlusive device for inserting into body cavities or vesicles. More particularly, it is a vasoocclusive device which, as used, is in the approximate shape of an anatomical cavity. It may be ultimately deployed as a substantially spherical shape in the operable config

 
 
  Recently Added Patents
Communication apparatus, integrated circuit, and communication method
Communication system, authentication device, control server, communication method, and program
Perfume bottle
Real-time application of filters based on image attributes
Dry-cooling unit with gravity-assisted coolant flow
Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
Load balancing in shortest-path-bridging networks
  Randomly Featured Patents
Linear bearing devices
Methods for matching image-based texual information with regular expressions
Process and arrangement for spinning yarn
Semi-trailer leg
Assembly for coating a surface in a printing process
Compounds and compositions as hedgehog pathway inhibitors
Compact zoom lens system
Apparatus and method for trace stream identification of a pipeline flattener primary code flush following initiation of an interrupt service routine
Protective plate for a plasma display and a method for producing the same
Specific dielectric constant calibration method for an electromagnetic prober